Home
BridgeBio Pharma Reported Positive Phase 3 Results from FORTIFY the Phase 3 Pivotal Study of BBP-418 in People with Limb-Girdle Muscular Dystrophy Type 2I/R9

BridgeBio Pharma Reported Positive Phase 3 Results from FORTIFY the Phase 3 Pivotal Study of BBP-418 in People with Limb-Girdle Muscular Dystrophy Type 2I/R9

Today’s Highlights October 27, 2025

BridgeBio Pharma

BridgeBio Pharma, Inc. is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. The Company was founded in 2015. Its team of experienced drug discoverers, developers and innovators is committed to applying advances in genetic medicine to help patients as quickly as possible.

BridgeBio Pharma in the NEWS

Today, BridgeBio Pharma, Inc. (This content is for paid subscribers.

Please click here to subscribe or here to log in.
Today’s Highlights
October 27, 2025

Other Articles